Table 3.

The participant data in the Gum olibanum resin powder (1) group (n=37) and the placebo (2) group (n=34) at baseline and after 12 weeks of the trial.

Parameters	Baseline mean (SD)		p-value	Endpoint mean (SD)		p-value	Percent change Endpoint compared to baseline
FBS (mg/dL)	1	156.8 (10.5)	0.739	1	129.2 (9.1)	<0.001*	1	17.6 ↓
	2	156.1 (9.2)		2	153.9 (7.5)		2	1.4 ↓
HbA1c (%)	1	7.26 ( 0.47)	0.203	1	6.9 (0.38)	<0.001*	1	4.95 ↓
	2	7.42 ( 0.44)		2	7.41 (0.2)		2	0.13 ↓
Insulin (UI/L)	1	12.3 ( 6.3)	0.272	1	9.26 (2.7)	<0.001*	1	24.7 ↓
	2	10.84 ( 2.78)		2	10.1 (1.95)		2	6.8 ↓
Chol (mg/dL)	1	173.2 (27.1)	0.878	1	162.3 (27.5)	0.003*	1	6.3 ↓
	2	172.4 ( 42.5)		2	175.7 ( 29.1)		2	1.92 ↑
LDL (mg/dL)	1	101.7 (24.8)	0.6	1	88.4 (23.3)	<0.001*	1	13.1 ↓
	2	98.6 (25.02)		2	97.3 (23.1)		2	1.4 ↓
TG (mg/dL)	1	176.1 (44.5)	0.246	1	164.6 ( 38.4)	<0.001*	1	6.53 ↓
	2	171.1 ( 36.8)		2	172.5 ( 33.3)		2	0.81 ↑

P< 0.05 was considered as statistically significant.